SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is a key trending stock following the FDA approval of its oral Wegovy, marking the first GLP-1 pill for weight management. The community views this as a significant game-changer, offering convenience over injections and potentially giving NVO a crucial first-mover advantage against competitors like Eli Lilly in the expanding obesity market. Many investors believe this catalyst, coupled with the stock's perceived undervaluation, positions Novo Nordisk for a substantial rebound despite some initial market skepticism.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is experiencing a surge in conversation driven by the "Green Revolution" narrative, as community members highlight its role as the preferred blockchain for cannabis-related projects. Recent discussions center on federal policy shifts, such as the Schedule III reclassification and the implications of the 280E tax changes, which are seen as significant catalysts for tokens building on Solana. This momentum is fueling bullish sentiment, with many viewing Solana's speed and efficiency as critical for the future of on-chain cannabis finance.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is experiencing highly polarized sentiment as analysts issue conflicting outlooks, raising long-term price targets based on AI and robotaxi potential while simultaneously cutting near-term delivery estimates due to softening EV demand. The community is sharply divided, with bulls advocating to "buy the dip" for a push to new highs, while bears highlight the company's high valuation and unfulfilled promises amidst decelerating sales. Traders are actively debating whether the stock can overcome significant resistance and sustain its recent rally.

Sable Offshore Corp. engages in offshore oil and gas field operations. It focuses on developing the prolific Santa Ynez Unit in federal waters offshore California. The company was founded by James C. Flores on October 16, 2020 and is headquartered in Houston, TX.

Sable Offshore Corp.

Sable Offshore Corp. is trending following federal approval to restart its Las Flores Pipeline, a critical development that places regulatory authority under federal oversight and bypasses previous state-level hurdles. This news has generated strong bullish sentiment within the community, with many seeing it as a significant de-risking event for the company's California offshore oil assets. Traders are actively discussing the potential for a momentum-driven rally and short squeeze, even amidst lingering concerns about Sable Offshore's financial standing.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is gaining traction following the initiation of a token buyback program, utilizing recent revenue and a portion of its DAO treasury to foster sustainable network value. The community is actively discussing its strong potential, highlighting its role as a crucial oracle solution, especially for real-world asset integration, and views these actions as a significant bullish catalyst.

Starfighters Space Inc

Starfighters Space Inc. (FJET) is a focal point of discussion following extreme post-IPO volatility, marked by a significant price drop after an initial surge. Community sentiment is sharply divided, with some anticipating a short squeeze and substantial bounce due to low float and high short fees, while others warn of a 'pump and dump' given the company's pre-revenue status and questioned fundamentals. Traders are actively debating the speculative nature of this aerospace sector play.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

The SPDR Dow Jones Industrial Average ETF (DIA) is trending as the broader market experiences significant upside, with many celebrating new record highs and anticipating a 'Santa Rally'. Community discussions highlight the Dow's robust performance, supported by strong economic data like GDP figures and a perceived rotation into traditional industrial and financial sectors. This momentum suggests underlying market strength, although some investors express caution about current valuations.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI CRYPTO is capturing attention, largely fueled by its "We're All Gonna Make It" ethos and a highly engaged community. Discussions highlight strong bullish sentiment, increasing platform visibility, and enthusiasm for its future within the crypto space.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

Hycroft Mining Holding Corp

Hycroft Mining is trending due to recent drill results revealing high-grade silver in its Vortex system, exciting investors about the potential of its Nevada mine amidst a strengthening precious metals market. This positive exploration news is amplified by notable institutional buying, though community discussion is divided between bullish predictions for significant gains and concerns about potential share offerings and past stock performance.

VisionWave Holdings, Inc. engages in the forefront of revolutionizing defense capabilities by integrating advanced artificial intelligence (AI) and autonomous solutions across air, ground, and sea domains. The company was founded on September 3, 2024 and is headquartered in Wilmington, DE.

VisionWave Holdings Inc.

VisionWave Holdings, Inc.

VisionWave Holdings is trending following the issuance of a new U.S. patent for its core RF imaging and AI technologies, combined with the recent acquisition of Solar Drone Ltd., which expands its presence in defense and autonomous systems. The community is actively discussing the stock's extremely low float and perceived short interest, anticipating a potential squeeze, especially as the company recently filed complaints regarding abnormal market activity.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Credit-Card Sized Device Wins FDA Clearance for At-Home Heart Monitoring

Cardiac care is undergoing a fundamental shift as technology enables patients to capture critical health data outside traditional medical settings. The ability to record meaningful cardiac information during symptomatic episodes, rather than hours or days later in a doctor's office, represents a paradigm change in how physicians diagnose and manage heart conditions affecting millions of Americans.Shares of HeartBeam, Inc. (NASDAQ: BEAT) are surging Wednesday after the company announced FDA 510(k) clearance for its groundbreaking 12-lead electrocardiogram (ECG) synthesis software for ...

<ul class="summary-bullets"><li>The clearance enables HeartBeam’s cable-free technology to capture the heart’s electrical signals in three dimensions.</li><li>The approval follows a successful appeal of a prior Not Substantially Equivalent (NSE) determination.</li><li>The company intends to roll out a controlled commercial launch in early 2026.</li></ul>HeartBeam, Inc. (BEAT) on Wednesday announced that the U.S. Food and Drug Administration (FDA) has cleared its 12-lead electrocardiogram (ECG) synthesis software for arrhythmia assessment, which enables its cable-free technology to capture the heart’s electrical signals in three dimensions and convert them into a complete 12-lead ECG.The approval follows a successful appeal of a prior Not Substantially Equivalent (NSE) determination, marking a significant milestone for the company.<h2 class="st-heading-2">Why It Matters?</h2>Unlike traditional single-lead or 6-lead devices, this innovation allows patients to obtain accurate cardiac readings from home, with synthesized results promptly reviewed by board-certified cardiologists.Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/BEAT">HeartBeam’s stock</a> traded over 72% higher in Wednesday’s premarket. On Stocktwits, retail sentiment around the stock jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day, while message volume shifted to ‘high’ from ‘low’ levels in 24 hours.&nbsp;<blockquote>“We look forward to initiating our U.S. market introduction while advancing our efforts on heart attack detection, an on-demand 12-lead extended wear patch, and AI-based screening and prediction algorithms trained on our unique longitudinal data.”-Robert Eno, CEO, HeartBeam</blockquote><h2 class="st-heading-2">Limited U.S. Launch Planned</h2>The company intends to roll out a controlled commercial launch in early 2026, targeting select concierge and preventive cardiology groups that have expressed strong interest.&nbsp;It has developed a working prototype of an extended-wear 12-lead ECG patch, designed to provide continuous cardiac monitoring. As HeartBeam’s 3D ECG platform adoption grows, the resulting data repository will enable longitudinal analysis. The company plans to use this data to develop AI-based screening and predictive algorithms.BEAT stock has lost over 64% in 2025 and over 73% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lucid-signals-tough-road-ahead-amid-slumping-ev-demand-ceo-says-there-is-a-slowdown-there-s-no-question-about-it/cLIHRZWRENx">Lucid Signals Tough Road Ahead Amid Slumping EV Demand: CEO Says ‘There Is A Slowdown, There’s No Question About It’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Atrial tachycardia electrocardiogram, heart rhythm disorder where the patient complains of rapid palpitation sensations.

Why Did BEAT Stock Rocket 72% In Pre-Market Today? 

The FDA has cleared HeartBeam’s 12-lead electrocardiogram synthesis software for arrhythmia assessment.

Equity

The FDA has cleared HeartBeam’s 12-lead electrocardiogram synthesis software for arrhythmia assessment.


What's Behind HeartBeam's Over 40% After-Hours Surge?

HeartBeam shares jumped 40.75% in after-hours trading after the company outlined its regulatory strategy following the FDA's Not Substantially Equivalent decision.read more...

HeartBeam Provides Update on Regulatory Path Following FDA Decision on 12-Lead ECG Synthesis Software Application

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced its regulatory strategy following...

<ul class="summary-bullets"><li>Roth Capital sees potential FDA clearance for the software.</li><li>The FDA may want the company to use a different predicate device, pursue a different regulatory pathway, or provide additional data, the analyst said.&nbsp;</li><li>HeartBeam is now evaluating launching its 3D ECG system, which received FDA clearance in December 2024.</li></ul>Shares of HeartBeam, Inc. (BEAT) slumped 58% on Friday afternoon after the company said that the U.S. Food and Drug Administration refused clearance for its 12-Lead Electrocardiogram (ECG) Synthesis Software for arrhythmia assessment.The medical technology company said that it received a ‘not substantially equivalent’ letter from the FDA. A "Not Substantially Equivalent" (NSE) letter is an official notification from the FDA stating that a new medical device is not considered substantially equivalent to a legally marketed predicate device.The company said that it will be working with the agency to get to a resolution and expressed confidence in its clinical data. Earlier this month, HeartBeam had touted FDA clearance for the software as a major inflection point for the company.The company is now evaluating launching its 3D ECG system which received FDA clearance in December 2024.<h2 class="st-heading-2">Analyst Takeaway</h2>Roth Capital, however, sees potential FDA clearance for the software. The FDA may want the company to use a different predicate device, pursue a different regulatory pathway, or provide additional data, it said.While resolving the pathway for the 12-lead ECG synthesis software, management may decide to roll out the foundational 3D ECG system to concierge medical practices, preventive cardiology clinics, and hospital-at-home programs, the analyst said, as per The Fly.The analyst kept a ‘Buy’ rating on HeartBeam with a $4 price target. The price target represents a potential upside of over 138% from the stock’s closing price on Thursday.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BEAT">BEAT stock</a> rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user echoed Roth Capital’s opinion and said that the stock would beat $5 on FDA approval.<stembedurl>https://stocktwits.com/jamestocklover/message/637108009</stembedurl>Another noted that an NSE letter is not the end.<stembedurl>https://stocktwits.com/Rolltide2020/message/637103348</stembedurl>BEAT stock is down by 70% this year and by about 75% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/will-scot-stock-surges-after-baird-upgrade-analyst-calls-q3-a-watershed-quarter/cLPMv4RREfb">WillScot Stock Surges After Baird Upgrade – Analyst Calls Q3 A ‘Watershed Quarter’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

HeartBeam Stock Slumps After FDA Refuses Clearance For ECG Software

The company said it will work with the agency to reach a resolution and expressed confidence in its clinical data.

HeartBeam Reports Third Quarter 2025 Results

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, has reported its financial and operational results for...

HeartBeam Earnings Preview

HeartBeam to Host Third Quarter 2025 Results Conference Call on Thursday, November 13, 2025 at 4:30 p.m. Eastern Time

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Thursday, November 13...

HeartBeam Teams Up With HeartNexus to Deliver Cardiologist-Level ECG Insights Anytime, Anywhere

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced a partnership with HeartNexus, Inc., a...

HeartBeam, Inc. is a development stage company, which engages in cardiovascular diagnostic technology. Its electrocardiogram (ECG) collection device provides physicians with cardiac diagnostic information for a patient that is outside of a medical institution. The device sends ECG signals to the patient's smartphone and on to a cloud-based software expert system. The company was founded by Branislav Vajdic in 2015 and is headquartered in Santa Clara, CA.

Current Price	$2.85
Prev Close	$2.93
Open	$2.79
Dividend Yield	0.00%
50-Day Moving Average	$1.61
Beta	1.13
Avg. Volume	6.45M
PE Ratio	-4.41

52-Week High	$4.00
52-Week Low	$0.54
Market Capitalization	$100.92M
EPS (Annual)	-$0.7299
Price to Book	247.88
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

BEAT
HeartBeam Inc

Feed

News

Sentiment

Fundamentals

Info

Latest BEAT News

BEATHeartBeam Inc